- Recruiting
NCT04258683: Phase 2: Pembrolizumab Added to the Standard First-Line therapy (CyBorD) for NDMM NTE
Updated: Oct 12, 2022
NCT04258683: Phase 2: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

NCT04258683: Phase 2: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed patients with multiple myeloma that are not eligible for autologous stem cell transplantation.
Sponsor
Canadian Myeloma Research Group
Collaborator
Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier: NCT04258683
Official Title: A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation
First Posted : February 6, 2020
Click here to see details